COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 1208: Articles 12071-12080  | Next

Consequences of COVID-19 vaccine allocation inequity in Chicago
Zeng, S., Pelzer, K. M., Gibbons, R. D., Peek, M. E., Parker, W. F.
10.1101/2021.09.22.21263984 — Posted: 2021-09-23 Discussion: Onsite
Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer
Parikh, R. B., Takvorian, S. U., Vader, D., Wileyto, E. P., Clark, A. S., Lee, D. J., Goyal, G., Rocque, G. B., Dotan, E., Geynisman, D. M., Phull, P., Spiess, P. E., Kim, R. Y., Davidoff, A. J., Gross, C. P., Neparidze, N., Miksad, R. A., Calip, G. S., Hearn, C. M., Ferrell, W., Shulman, L. N., Mamtani, R., Hubbard, R. A., P.R.A.C.T.I.C.E: Pandemic-Related Advanced Cancer Treatment In the COVID-19 Era
10.1101/2021.09.22.21263964 — Posted: 2021-09-23
Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor
Danziger, O., Patel, R. S., DeGrace, E. J., Rosen, M. R., Rosenberg, B. R.
10.1101/2021.09.22.461286 — Posted: 2021-09-23
Deciphering the role of the Pancreatic Secretome in Covid-19 associated Multi-Organ Dysfunctions
Pathak, E., Mishra, R.
10.1101/2021.09.22.461447 — Posted: 2021-09-23
Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home, Osnabrueck, Germany, January-March 2021
Meyer, E. D., Sandfort, M., Bender, J. K., Matysiak-Klose, D., Doerre, A., Bojara, G., Beyrer, K., Hellenbrand, W.
10.1101/2021.09.13.21262519 — Posted: 2021-09-23
Successive pandemic waves with more virulent strains, and the effects of vaccination for SARS-CoV-2
Castro e Silva, A., Bernardes, A. T., Barbosa, E., Dattilo, W., Ribeiro, S. P.
10.1101/2021.09.21.21263901 — Posted: 2021-09-23
Identifying The "Core" Transcriptome of SARS-CoV-2 Infected Cells
Nour, E. T., Tran, R., Afravi, A., Pei, X., Davidian, A., Kadandale, P.
10.1101/2021.09.22.461142 — Posted: 2021-09-23
Demographic Analysis of Mutations in Indian SARS-CoV-2 Isolates
Parekh, N., Agarwal, K.
10.1101/2021.09.22.461342 — Posted: 2021-09-23
The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose
Fiorino, F., Sicuranza, A., Ciabattini, A., Santoni, A., Pastore, G., Simoncelli, M., Polvere, J., Galimberti, S., Auddino, S., Barate', C., Montagnani, F., Sammartano, V., Bocchia, M., Medaglini, D.
10.1101/2021.09.21.21263627 — Posted: 2021-09-23
Risk Factors for Low Humoral Response to BNT-162b2 In Hemodialysis Patients
Duarte, R. A., Figueiredo, C., Luz, I., Ferrer, F., Goncalves, H., Sofia, F., Lopes, K., Lobos, A. V.
10.1101/2021.09.21.21263568 — Posted: 2021-09-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).